Vigabatrin
Back to searchMolecule Structure
Scientific Name
Vigabatrin
Description of the Drug
Vigabatrin is an irreversible GABA transaminase inhibitor used as an adjunct therapy to treat refractory complex partial seizures in patients ≥2 years unresponsive to alternatives. May also be used as monotherapy to treat infantile spasms in infants 1 month to 2 years.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB01080
http://www.drugbank.ca/drugs/DB01080
Brand Name(s)
Sabril
Company Owner(s)
Alkem Laboratories Ltd, Invagen Pharmaceuticals Inc, Elite Laboratories Inc, Granules Pharmaceuticals Inc, Amneal Pharmaceuticals Of New York Llc, Propel Pharma Corp, Specgx Llc, Aurobindo Pharma Ltd, Accord Healthcare Inc, Lupin Ltd
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Gamma-amino-N-butyrate transaminase | SINGLE PROTEIN | INHIBITOR | CHEMBL2044 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL26714 | ||||
| PharmGKB | PA10231 | ||||
| Human Metabolome Database | HMDB0015212 | ||||
| DrugBank | DB01080 | ||||
| PubChem: Thomson Pharma | 15194489 | ||||
| PubChem | 5665 | 25202592 | |||
| LINCS | LSM-4959 | ||||
| Nikkaji | J82.341D | ||||
| BindingDB | 50118886 | ||||
| EPA CompTox Dashboard | DTXSID4041153 | ||||
| DrugCentral | 2819 | ||||
| Brenda | 91632 | 3140 | 91636 | 213168 | 23509 |
| ChemicalBook | CB1285620 | ||||
| Guide to Pharmacology | 4821 | ||||
| rxnorm | SABRIL | VIGABATRIN | |||
| PubChem: Drugs of the Future | 12012774 | ||||
| KEGG Ligand | C07500 | ||||
| ChEBI | 63638 |
